QIAGEN

200 Hathersage Rd, Manchester
Manchester
M13 0BH

Visit Now →

View on map
0808 234 3974
Get here sustainably

QIAGEN, a global leader in molecular testing and clinical diagnostics, established its UK presence in 2009 by acquiring DxS, a pioneering diagnostics company based at the Manchester Incubator Building on Grafton Street. The acquisition, supported by MIDAS (Manchester’s inward investment agency), was driven by Manchester’s thriving life sciences ecosystem and strong growth potential.

Since then, QIAGEN’s integration and evolution in Manchester have been marked by steady expansion. Initially, DxS was assimilated into QIAGEN’s global business activities to spearhead the development of companion diagnostics to help guide treatment decisions, particularly for cancer patients. Over time, the site developed into a critical innovation engine, growing its R&D and commercial capabilities and adding specialised functions in clinical affairs, regulatory and quality assurance. Today, QIAGEN’s Manchester team has about 350 professionals and growing.

QIAGEN’s UK headquarters are now based at Citylabs 2.0, a state-of-the-art biomedical facility that houses QIAGEN’s Global Centre of Excellence for Precision Medicine. This location not only anchors their UK strategy but also plays a central role in shaping global diagnostics innovation.

QIAGEN serves over 500,000 customers worldwide, delivering “Sample to Insight” solutions that help its customers make improvements in life possibly by gaining insights into the building blocks of life – DNA, RNA, and proteins.

Manchester, and specifically the Oxford Road Corridor, was chosen as the company’s UK hub for its direct access to scientific talent and research excellence at the University of Manchester.

This relationship has grown to include annual undergraduate placements and contributions to academic programs such as the Molecular Diagnostics course.

In July 2022, QIAGEN deepened its collaboration with Manchester University NHS Foundation Trust (MFT) through a Memorandum of Understanding (MoU), enabling cross-disciplinary knowledge exchange between clinicians and diagnostic experts. Collaborative opportunities within the campus ecosystem have also fueled innovation; during the COVID-19 pandemic, QIAGEN partnered with Affinity Biomarker Solutions and the University of Manchester to support patient testing using high-throughput automation platforms—simultaneously running routine PCR diagnostics and introducing new commercial tests.

Get the latest news from Oxford Road in your inbox

Please note you can request us to remove your details from our records at any time.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Analytics Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.